The Problem This Page Is Usually Asked to Solve
You track your sleep. You have tuned your nutrition, your training and your recovery. And you have noticed that the returns are flattening — recovery that took 48 hours now takes 72, and the trend lines you watch have stopped moving.
That observation is accurate. Cellular aging does proceed largely independently of how well you manage your inputs, and no amount of discipline stops it.
The question is what follows from it. The usual answer offered to people in this position is that there is a further tier of intervention available for purchase. This page takes the question seriously and gives the honest answer instead, which is more mixed and, in places, more useful.
"Biohacker" is an audience, not a diagnosis. Being health-conscious, well-informed and 45 is not a medical indication for anything. That is worth stating plainly, because the entire commercial case for cell therapy in this group rests on treating an audience as though it were a condition.
What Is Established About Cellular Aging
This part is solid, and it is worth understanding on its own terms.
The 2023 revision of the hallmarks-of-aging framework describes twelve interconnected processes, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, cellular senescence and stem cell exhaustion. [1]It is the standard map of the field.
Cellular senescence. Cells that have stopped dividing but have not died accumulate with age and secrete an inflammatory mixture known as the senescence-associated secretory phenotype. [3]In mice, a transgenic system that selectively kills p16^Ink4a^-positive cells extended median lifespan in two genetic backgrounds and delayed deterioration in kidney, heart and fat tissue. [4]That result is in mice, using a genetic tool that does not exist for humans, and it is the foundation of the entire senolytics field.
Inflammaging. Chronic, low-grade, sterile inflammation rises with age and is associated with most age-related disease. [2]Senescent cells and immune cells communicate through both classical secreted signals and extracellular vesicles, and this crosstalk is one proposed mechanism sustaining that state. [6]
Stem cell exhaustion. Endogenous repair capacity declines with age — fewer cells, less responsive. [5]Bone-marrow MSC numbers obtained by aspiration fall with donor age, and markers of oxidative damage and senescence in those cells rise. [9]
All four are real. None of them establishes that infusing donor cells reverses any of them in a person who is well.
What Has the Strongest Evidence
Before treatment options, the interventions with the best outcome data — because on a page about optimisation this is the section that should carry the most weight, and it usually carries the least.
These are not preliminaries to clear before the real intervention. In this population they are the best-evidenced interventions that exist, measured against outcomes that matter rather than markers that move.
Cardiorespiratory fitness. In 122,007 patients undergoing exercise treadmill testing, higher fitness was associated with lower long-term mortality with no observed upper limit of benefit; the adjusted risk associated with the lowest fitness quintile was comparable in magnitude to that of established clinical risk factors. [19]This is observational and cannot prove causation, but it is a very large dataset with a consistent gradient.
Muscular strength. In the PURE study — 139,691 participants across 17 countries — grip strength was inversely associated with all-cause mortality, cardiovascular mortality and myocardial infarction, and predicted death more strongly than systolic blood pressure did. [18]Grip strength is the "vitality marker" often invoked on pages like this one; this is the study that actually supports its importance, and it measures the trait, not a treatment effect on it.
Physical activity, including resistance training. The WHO 2020 guidelines recommend 150–300 minutes of moderate or 75–150 minutes of vigorous aerobic activity per week, plus muscle-strengthening activity on two or more days per week, and note that some activity is better than none across all adult age groups. [20]
The unglamorous cardiovascular basics. Not smoking, and treating elevated blood pressure and lipids, remain the interventions with the largest randomised evidence for extending healthy life. They are absent from most optimisation marketing because they are cheap and already available.
Sleep. Sleep is genuinely foundational, and the emphasis placed on it in optimisation circles is warranted.
If the goal is to be functionally and physiologically younger at 60 than your peers, the honest ranking puts these first — not as prerequisites, but as the intervention.
What the MSC Evidence Actually Is
The mechanism, stated correctly
Mesenchymal stromal cells do not engraft, do not replace your cells, and do not differentiate into your tissues in any meaningful quantity after intravenous infusion. Their originator has argued at length that the name "stem cell" is misleading and that they should be understood as medicinal signalling cells, acting through secreted factors that modulate the local tissue environment. [7]
This is the honest mechanistic story, and it is more modest than the marketing version. It also means that any effect is transient by nature: the cells are largely cleared within days.
Cells from different sources do differ. Neonatal tissue sources — umbilical cord, placenta — and adult sources (marrow, adipose, peripheral blood) vary in expansion capacity and secretory profile, and neonatal sources generally expand more readily. [8]That is a laboratory comparison, not a clinical outcome comparison, and it does not by itself establish that one source works better in patients.
The one randomised head-to-head that exists compared allogeneic with autologous MSCs in 37 patients with non-ischaemic dilated cardiomyopathy, delivered by transendocardial injection. The allogeneic group improved on the six-minute walk (+37.0 m, p = 0.04) where the autologous group did not (+7.3 m, p = 0.71), with a significant between-group difference (p = 0.017). [13]That is one trial, in one heart disease, by a delivery route that is not intravenous infusion — but it is the closest thing to direct evidence that donor cells outperform your own, and it points in that direction.
The clinical data, in full
Two trials. Same programme, same centre, frail elderly patients.
Phase I (n=15): non-randomised, non-blinded, dose-escalation — 20, 100 or 200 million cells, five patients each, no placebo group. Six-minute walk distance increased at 3 and 6 months and TNF-α fell at 6 months. [10]Because there was no control group, those changes cannot be attributed to the infusion.
Phase II (n=30): randomised, double-blind, placebo-controlled — 100 million, 200 million, or placebo. The 100-million group improved on the six-minute walk (p = 0.011), the short physical performance battery (p = 0.031) and FEV₁ (p = 0.025). Immunological markers improved in both dose groups relative to placebo. [11]
Both are described in a review of the programme as showing that cell therapy is a plausible direction for frailty specifically. [12]
Three things this evidence does not do:
- It does not speak to healthy people. Frailty is a defined syndrome of decline in lean mass, strength, endurance, gait speed and physiologic reserve. Enrolled patients had it. If you are training four times a week and asking about optimisation, you are not the population studied, and there is no basis for assuming the same result.
- It does not support "higher dose, better effect." The opposite. In Phase II the 200-million group showed no improvement in the six-minute walk (p = 0.263), the physical performance battery (p = 0.812) or FEV₁ (p = 0.259), and showed a reduction in measured activity (p = 0.008). In Phase I the 100-million dose gave the best result across parameters. A survey of 914 MSC trials found minimum effective doses clustering at 100–150 million, with lower and higher intravenous doses both less effective. [14]
- It does not show improved grip strength. Grip strength was measured in both trials and did not change in either — explicitly reported as non-significant in Phase I and at p = 0.676 in Phase II. [10][11]It is worth naming because grip strength is exactly the marker most often claimed for these treatments.
Durability
There is no durability evidence for this use. The longest follow-up in the trials above is 12 months in patients with dilated cardiomyopathy, [13]and 6 months in the frailty trials. [10][11]Claims of benefit persisting one to two years in healthy adults have no source.
NAD⁺
NAD⁺ declines with age and is required for sirtuin activity and mitochondrial function; this biology is well characterised. [16]What is not established is that intravenous NAD⁺ raises NAD⁺ in human tissues, or that giving it before a cell infusion improves the result of that infusion. No human trial has tested either. Anyone offering NAD⁺ as "priming" is describing a rationale, not a finding.
Exosomes
MSC-derived extracellular vesicles are an active research area with real preclinical results — for example, reduced damage in a rat model of laser-induced retinal injury, partly through inhibition of MCP-1. [17]There is no human trial testing whether administering exosomes before an MSC infusion improves anything, and no trial testing the day-1-exosomes, day-2-cells sequence commonly sold. A sequencing claim requires a study that varies the sequence. None exists.
Senescent-cell clearance in humans
Because senescence is invoked so often in this context, here is the entire human dataset. Two small open-label studies of dasatinib plus quercetin: 14 patients with idiopathic pulmonary fibrosis, where the primary endpoints were feasibility measures, [21]and 9 patients with diabetic kidney disease, the first study to show directly that senolytics reduce senescent cell burden in humans. [22]Both are tiny, uncontrolled, in sick patients, and use oral drugs — not cell infusions.
That is the state of the art. MSC infusion has not been shown to clear senescent cells in humans at all.
Safety
Who should not receive intravenous cell therapy:
- Anyone with an active or recently treated malignancy, or under surveillance for one
- Anyone on immunosuppressive therapy, or with an active infection
- Anyone pregnant or breastfeeding
- Anyone whose symptoms have not been evaluated — fatigue, declining recovery and cognitive change have common medical causes (thyroid disease, anaemia, sleep apnoea, depression, medication effects, diabetes) that are diagnosable and treatable, and an infusion will not address any of them
What the safety evidence covers. The most-cited review identified 36 studies with 1,012 participants receiving intravascular MSCs; 8 were randomised, enrolling 321 participants between them. Meta-analysis found no association with acute infusional toxicity, organ-system complications, infection, death or malignancy — and a statistically significant association with transient fever. [15]The authors concluded that the therapy appears safe on current evidence and called for larger controlled trials with more rigorous reporting.
What that does and does not mean. It is a genuinely reassuring short-term safety signal, and it should be reported as such. It is also 1,012 people, mostly with serious illness, mostly followed for months rather than years. It is not a basis for claiming long-term safety in healthy people receiving repeated annual infusions, because nobody has studied that.
Known short-term effects include transient fever, fatigue and infusion-site reactions.
Allogeneic cells carry an immunological consideration. In the dilated cardiomyopathy trial, one allogeneic recipient developed a donor-specific calculated panel reactive antibody level above 80%. [13]Sensitisation can matter later if a person ever needs a transplant or transfusion.
Who This Is and Is Not For
There is no evidence-based candidacy profile for optimisation, because the trials that would define one have not been done. What follows is therefore framed as questions to ask, not criteria to meet.
Address first, and consider whether they are the whole answer:
- Untreated sleep-disordered breathing — a common and highly treatable cause of exactly the symptoms that prompt this enquiry
- Metabolic dysfunction, elevated blood pressure or lipids
- Any new or unexplained symptom that has not been evaluated by a clinician
- Whether current training includes resistance work and sufficient aerobic volume [20]
Reasonable questions to put to any clinic:
- What is the evidence in people like me, specifically? (There is none from randomised trials.)
- What dose, and why — given that 100 million outperformed 200 million in both published trials? [10][11]
- What outcome, measured how, and compared with what?
- What is the total cost, including repeat treatments?
NK/NKT cell therapy
Natural killer and NK T-cell therapies are sometimes offered alongside MSC infusion for "immune optimisation" in healthy adults. There is no clinical trial evidence supporting that use. These are cell therapies with a genuine and active evidence base in oncology, which is a different setting with different risks, different endpoints and sick patients who have exhausted other options. Their oncology record does not transfer to healthy adults, and no study has tested them for immune optimisation.
Measuring Whether Anything Worked
This deserves more scepticism than it usually gets.
A biomarker moving is not a benefit occurring. If hs-CRP falls from 1.4 to 0.9, nothing has been demonstrated about how long or how well you will live. Inflammatory markers are correlated with outcomes across populations; moving one in an individual has not been shown to change that individual's outcome.
Serial testing without a control produces false signals. Measure a panel of markers twice and some will move, through day-to-day biological variation and regression to the mean — the ones that were extreme at baseline will tend to be less extreme on retest whether or not anything was done. With no comparison group and no blinding, an apparent improvement is expected even from an inert intervention. This is precisely why the frailty trials needed a placebo arm, and why the uncontrolled Phase I result cannot be attributed to the cells.
If you want to measure something meaningful, measure function. Six-minute walk distance, gait speed, chair-stand time, VO₂max and grip strength are validated, cheap, and connected to outcomes that matter. [18][19]Two of them are what actually moved in the frailty trials. None requires a treatment to be worth tracking.
On biological-age tests. This page makes no claim about epigenetic or biological-age clocks, and readers should be cautious about products that do. These are research tools with meaningful measurement variability between assays; they have not been validated as an endpoint for judging whether an individual's treatment worked.
Frequently Asked Questions
Q: Is stem cell therapy for optimisation approved anywhere?
A: In the United States, MSC therapy for optimisation is not FDA-approved and is considered investigational. Treatment is offered in a number of other jurisdictions under a range of regulatory arrangements. The availability of a treatment in a particular country is not evidence that it works — it reflects that country's regulatory framework, which is a separate question from efficacy. Specific claims about any national regulator's oversight of a specific clinic should be verified directly with that regulator rather than accepted from a clinic.
Q: What would change the picture?
A: A randomised, placebo-controlled trial in healthy adults, with functional endpoints, adequate duration and a pre-registered protocol. Nothing smaller resolves the central question, because the effects claimed in this population are exactly the sort that uncontrolled studies generate spuriously.
Q: How is this different from other things I have tried?
A: Most interventions in this space modulate an existing system. MSC infusion introduces signalling cells that are cleared within days. [7]Whether that produces lasting change in a healthy person is the open question, and it is open in the strict sense: not "probably yes, pending confirmation," but untested.
Q: Can I combine this with what I already do?
A: Nothing here suggests stopping training, sleep or nutritional practices — those carry the better evidence and should continue regardless. Any supplement or medication should be discussed with the treating clinician, particularly immunosuppressants. Be sceptical of the word "synergy": establishing that two interventions add to each other requires a study designed to test that, and for these combinations none has been done.
Q: What is the difference between stem cells and exosomes?
A: Exosomes are vesicles secreted by cells, carrying proteins and nucleic acids; they are one route through which MSCs exert effects. Exosome products are not equivalent to cell therapy, have their own regulatory status, and have not been shown in human trials to improve outcomes when given before an infusion. [17]
Q: Are there risks?
A: See the Safety section above. Short-term safety data in 1,012 participants is reassuring and includes a significant association with transient fever. [15]Long-term safety in healthy adults receiving repeated infusions has not been studied. The most substantial risk for a well person is not a specific adverse event — it is spending significant money and attention on an intervention with no demonstrated benefit in their situation, while a treatable cause of their symptoms goes undiagnosed.
The Honest Summary
The biology is real. Cells age, senescent cells accumulate, inflammation rises, repair capacity falls. [1][2][3][5]
The treatment is unproven in the people asking about it. Forty-five frail elderly patients at one centre is a legitimate early signal in frailty, and it is not evidence for healthy adults. [10][11]The dose most often sold is above the one that worked. [14]The durability figures quoted have no source. The safety record is real, and smaller than usually stated. [15]
The interventions with the strongest evidence for staying functionally younger are the ones already available: strength, fitness, activity, sleep, and treating the ordinary cardiovascular risk factors. [18][19][20]They are not a checklist to complete before the real intervention. On current evidence, they are the intervention.
Anyone considering cell therapy on top of that is making a decision under genuine uncertainty. That is a defensible decision to make with clear eyes. It is not defensible to make it believing the evidence is stronger than it is.